Loading clinical trials...
Loading clinical trials...
A Phase 2a, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects With Moderate-to-Severe Atopic Dermatitis
Conditions
Interventions
MEDI9929
Placebo
Locations
29
United States
Research Site
North Miami Beach, Florida, United States
Research Site
Tampa, Florida, United States
Research Site
Arlington Hts, Illinois, United States
Research Site
Carmel, Indiana, United States
Research Site
Indianapolis, Indiana, United States
Research Site
Berlin, New Jersey, United States
Start Date
August 15, 2015
Primary Completion Date
May 9, 2016
Completion Date
July 15, 2016
Last Updated
February 15, 2018
NCT07217015
NCT07298395
NCT06116526
NCT06461897
NCT07262983
NCT06389136
Lead Sponsor
MedImmune LLC
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions